Stereotactic Body Radiation Therapy Followed by NALIRIFOX vs NALIRIFOX for Borderline Resectable Pancreatic Cancer

NCT06259058 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

96

Enrollment

OTHER

Sponsor class

Conditions

Pancreatic Cancer

Interventions

DRUG: Irinotecan liposome injection
DRUG: Oxaliplatin
DRUG: 5-Fluorouracil
DRUG: Leucovorin
RADIATION: SBRT

Sponsor

Tianjin Medical University Cancer Institute and Hospital